Other substances

Zinc sulfate

An inorganic dietary compound.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
2
 AI-suggested references
2
 Clinical trials

General information

Zinc sulfate is on the World Health Organization's List of Essential Medicines.

Zinc sulfate on DrugBank
Zinc sulfate on PubChem
Zinc sulfate on Wikipedia

Synonyms

White vitriol

 

Structure image - Zinc sulfate

[O-]S(=O)(=O)[O-].[Zn+2]

Supporting references

Link Tested on Impact factor Notes Publication date
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
RdRpol Small molecule Cohort study 		Patients 2.16

Although the adjunctive zinc sulphate therapy did not decrease the length of intensity care unit (ICU) stay, mechanical ventilation, or hospitalisation, it did decrease the frequency of ventilation need, ICU admission and death in non-ICU-requiring patients and increased the frequency of patient discharge in univariate analyses. Sample size: 411 (together with hydroxychloroquine and azithromycin) + 521 (hydroxychloroquine and azithromycin only). Dosage: 50 mg equivalent of elemental zinc twice daily for 5 days (with HCQ 400 mg on day one; 200 mg twice daily on days 2-5 + AZI 500 mg once daily).


 Sep/15/2020
Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IκBα-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry
Preprint In vitro 		Calu-3 and H322M

combination of azithromycin and zinc sulfate rapidly and synergistically suppresses ACE2 expression

 Jan/19/2021
Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19
Small molecule Non-randomized controlled open trial Phase I clinical trial Mild severity 		Mild COVID-19 patients 2.02

Zinc formulation not described in detail. In combination with ribavirin, ivermectin, and nitazoxanide. Observed improvement in SARS-CoV-2 nasopharyngeal viral clearance at days 7 and 15 compared to control. Sample size: 62 + 51 control. Dosage: 30 mg twice daily.

 Feb/16/2021

AI-suggested references

Link Publication date
Punicalagin and zinc (II) ions inhibit the activity of SARS-CoV-2 3CL-protease in vitro.
Jun/26/2020
Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study
Oct/28/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04370782 Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting Completed Phase 4 Apr/28/2020 Sep/30/2020
  • Alternative id - 20-21
  • Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - St Francis Hospital, Roslyn, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 18
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms
NCT04621461 Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting Completed Phase 4 Dec/20/2020 Feb/08/2021
  • Alternative id - 20-19
  • Interventions - Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - St. Francis Hospital - The Heart Center, Roslyn, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 3
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of participants hospitalized and/or requiring repeat emergency room visits|Number of participants admitted to the Intensive care unit (ICU)|Number of participants on a ventilator|All-cause mortality|Time to resolution of COVID-19 symptoms|Severity of symptoms
Export (.csv)